Comparison of the efficacies of three heartworm preventives against experimentally induced infections with Ancylostoma caninum and Toxocara canis in pups.
Forty 11- to 12-week-old helminth-naive Beagles were categorized by sex and weight and randomly assigned to 4 treatment groups (group 1, ivermectin/pyrantel pamoate; group 2, milbemycin oxime; group 3, untreated control; group 4, diethylcarbamazine/oxibendazole). Each pup was inoculated PO with approximately 100 infective Ancylostoma caninum larvae and 100 larvated Toxocara canis eggs on day 0, and repeatedly at 7-day intervals thereafter until day 56. Administration of anthelmintics also began on day 0, and subsequent treatments were administered according to label recommendations at 30-day intervals (groups 1 and 2) or daily (group 4) for a period of 90 consecutive days. Body weight and A caninum and T canis fecal egg counts were measured at weekly intervals, and clinical observations of health status were conducted twice daily. Pups were euthanatized on day 90, and total gastrointestinal worm burdens were determined. Compared with mean A caninum egg counts of group-3 control pups, egg counts in group-1 pups were significantly (P < or = 0.0001) lower on every sampling days 35, 42, 49, 63, 70, 77, and 84, and were consistently the highest of all treated groups, and egg counts of group-4 pups were significantly (P < or = 0.0001) lower on every sampling date from day 14 to day 90, and were consistently the lowest of all treated groups. Compared with mean A caninum egg counts of group-3 pups, egg counts in group-1 and group-2 pups were lower by 97.8 and 90.8%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Reinemeyer
C R
CR
Department of Environmental Practice, College of Veterinary Medicine, University of Tennessee, Knoxville 37996-4500, USA.
Faulkner
C T
CT
Assadi-Rad
A M
AM
Burr
J H
JH
Patton
S
S
D000367:Age Factors; D000704:Analysis of Variance; D000724:Ancylostomiasis / Q000517:prevention & control / Q000662:veterinary*; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D004049:Diethylcarbamazine / Q000627:therapeutic use; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D004359:Drug Therapy, Combination; D005260:Female; D007559:Ivermectin / Q000627:therapeutic use; D018942:Macrolides; D008297:Male; D010270:Parasite Egg Count; D011715:Pyrantel / Q000627:therapeutic use; D014120:Toxocariasis / Q000517:prevention & control*
D000871:Anthelmintics; D000900:Anti-Bacterial Agents; D001562:Benzimidazoles; D018942:Macrolides; C011321:oxibendazole; C078973:milbemycin oxime; D011715:Pyrantel; D007559:Ivermectin; D004049:Diethylcarbamazine